259 East Grand Avenue
South San Francisco
Freenome (free•nohm) is the dynamic collection of genetic material floating in your blood (cell-free) derived from the trillions of cells in your body. It is your living cell-free genome changing over time and space.
Founder and CEO: Gabriel Otte
Founder and COO: Riley Ennis
CTO: Michael Otte
CBO: Adam Drake
15 articles with Freenome
12/28/2018As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting
Freenome is presenting promising early data on its efforts to utilize machine learning to detect colorectal cancer (CRC) at its earliest stages, when treatment is most effective.
10/5/2018Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests
Freenome announced the creation of its IMPACT Advisory Board, a group tasked with helping Freenome’s leadership team optimize the company’s short- and long-term strategies, including those for its first commercial launch.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
QIAGEN N.V. announced a partnership with Freenome, a leading artificial intelligence (AI) genomics company, to accelerate the development and commercialization of next-generation sequencing (NGS) tests to enable precision medicine in cancer treatment.
Freenome’s platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies.
1/8/2018Freenome, headquartered in South San Francisco, is focused on developing a diagnostic test for early detection of cancer and other diseases on the so-called "liquid biopsy," in other words, blood.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
For nearly three decades, Dr. Scott has been an entrepreneur and visionary leader in genomic medicine.
Freenome announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in genomics and machine learning.